News

Vertex has discontinued Phase 1 development of its NaV1.8 inhibitor VX-961

BY      |     February 1, 2020

Vertex Pharmaceuticals, a global biotechnology company that develops medicines for people with serious diseases, announced that it has discontinued Phase 1 development of VX-961.

VX-961 was one of several NaV1.8 inhibitors developed by Vertex for the treatment of pain. Earlier, in 2018, Vertex dropped the development of VX-128 – another NaV1.8 inhibitor. Also, despite the positive Phase 2 data for its lead NaV1.8 inhibitor, VX-150, Vertex has not advanced it into late-phase trials since 2018.

Apparently, Vertex is searching for the best candidate to move into late-stage development. In line with this, Vertex plans to advance an additional molecule into clinical development in the first half of 2020.

Read more about Vertex here.


Image by Gerd Altmann from Pixabay


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.